The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ISAL 2023 | Session highlights: transforming AML treatment and building on new approaches
Charles Craddock, CBE, FRCP(UK), FRCPath, DPhil, University of Birmingham, Birmingham, UK, shares some insights into a session that took place at this year’s meeting, which focused on novel treatment approaches for patients with acute myeloid leukemia (AML). Topics that were covered include the important role of venetoclax and azacitidine in the management of patients unfit for intensive chemotherapy, triplet combinations being explored, and novel integrative approaches for fit patients. This interview took place at the 18th International Symposium on Acute Leukemias (ISAL XVIII), held in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
